Medical Billing for New Test Reduces Need for Colonoscopy
Medical Billing for New Test Reduces Need for Colonoscopy
Medical Billing for New Test Reduces Need for Colonoscopy
Medical billing reimbursement for colonoscopies may reduce in future years. The introduction of a new test called immunochemical fecal occult blood test (FOBT) is a better indicator of colon cancer. When used correctly, the immunochemical fecal occult blood test severely reduce the need for the colonoscopy in medical billing.
During a screening exam, patients usually take a test called guaiac FOBT. If patients test positive for this traditional test, the use of the new immunochemical fecal occult blood test would be in order.
Unfortunately, the old test produced many fake positives. This created the need for more colonoscopies to be performed. Colonoscopies are very intrusive and expensive. Reducing colonoscopy medical billing reimbursement would be great for physicians and patients alike.
For example, if a patient tests mildly positive during the guaiac FOBT test , they could undergo the new immunochemical fecal occult blood test instead of a colonoscopy. It is thought that the use of this new test will reduce colonoscopy medical billing by 30%.
The immunochemical FOBT Is more expensive than the guaiac FOBT test, But less expensive than a colonoscopy. This will lower your medical billing expenses and save your physicians and staff members a lot of time. The use of this new test will also please your payers. It’s always a good idea to impress the organization which gives you your medical billing reimbursement.
Another way to save money in your practice is to outsource your medical billing. You can save money on salaries, vacation pay, six leave, and holiday pay with medical billing companies. Outsourced personnel do not work for your practice, they work for the medical billing firm. This means you are not directly responsible for their paycheck. The responsibility medical billing firms hold can alleviate your practice of a lot of stress.
Be The First To Comment!
New comments are no longer accepted on this article.